Introduction
In recent years there is much interest in the design and development of DNA interactive molecules that can bind to DNA in a sequence selective manner. In spite of enormous efforts to design synthetic DNA intercalators, very few molecules are in clinical usage that exhibit sequence selectivity. The synthesis of small molecules which exhibit DNA sequence selectivity is of immense importance for targeting the rapid growth of tumour cells.
The pyrrolo [2,1-c] [1,4]benzodazepines (PBDs) are a group of naturally occurring antitumour antibiotics produced by various Streptomyces species and examples of which include anthramycin, tomaymycin, sibiromycin and DC-81. The formation of a covalent bond in the minor groove of DNA by nucleophilic attack of 2-amino group of a guanine base to form an aminal linkage to C-11 is responsible for the biological activities of PBDs. 
DC -81
SJG -136 8 11 Several flavonoid natural products have recently attracted attention as novel inhibitors of virus-associated reverse transcriptase.
14 These flavonoid derivatives also inhibit various cellular DNA polymerases by binding to the double stranded nucleic acid template-primer or by competing with it for a site on the enzyme. The DNA intercalation contributes to the cytotoxicity of the flavonoids. 15 In literature some flavonoids have been examined to induce enzymatic breakage by mammalian topoisomerase II. 16 Additionally the cytotoxic effects of flavonoids have demonstrated promising cytotoxicity against some selected human tumour cell lines. Taking advantage of the DNA interactive property of flavone moiety, it was considered of interest to link it to the PBD ring system through different alkane spacers for the preparation of new hybrids of PBD and evaluation of their DNA binding property as well as in vitro anticancer potential.
Results and Discussion
The precursor (2S)-N-[4-(n-bromoalkyloxy)-5-methoxy-2-nitrobenzoyl]-pyrrolidine-2-carboxaldehyde diethyl thioacetal 1a-c has been prepared following our previously described procedure. The DNA binding ability for these hybrids has been examined by using thermal denaturation assay with calf thymus (CT) DNA. 17 Table 1 . The results also demonstrate that increasing chain length from three to five reduces the DNA binding affinity. For CT-DNA alone at pH 7.00 ± 0.01, T m = 69. Primarily, compounds 4a-c have been evaluated for their in vitro cytotoxicity in selected human cancer cell lines of colon (HT-29, HCT-15), lung (A-549, HOP-62), cervix (SiHa) origin by using sulforhodamine B (SRB) method. 18 The results are expressed as percent of cell growth inhibition determined relative to that of untreated control cells (Table 2) . Usually, when the concentration of the compound solution is 10 -6 mol/L, the inhibition of the solution is more than 50%, and then compound is considered as an effective agent. According to this standard, it has been observed from Table 2 that 4a exhibit a strong effect to HT-29, HCT-15, HOP-62 cell lines and compound 4c suppressing HCT-15 and A-549 cell growth by 69% and 63%. The comparison of the data in Table 2 reveals the importance of an alkane spacer. As the alkane spacer increases from three to four the growth inhibition activity has decreased. This observation has been supported by thermal denaturation studies. In conclusion, we report the synthesis, DNA binding ability and in vitro cytotoxicity of the new PBD-flavone hybrids. These results show that an increase in linker chain length reduces the DNA binding affinity and in vitro growth inhibition of certain cancer cell lines. One of the hybrids with three carbon chain spacer (4a) exhibited significant DNA binding affinity as well as in vitro cytotoxicicty. 
2S)-N-4-[4-(2-Phenyl-4-oxo-4H-[1]benzopyran-6-yloxy)butoxy]-5-methoxy-2-nitrobenzoyl pyrrolidine-2-carboxaldehyde diethyl thioacetal (2b).
The compound 2b was prepared following the method described for the compound 2a, employing 1b (535 mg, 1 mmol) and the crude product was purified by column chromatography to afford the compound 2b as a yellow oil. (582 mg, 84% 
2S)-N-4-[5-(2-Phenyl-4-oxo-4H-[1]benzopyran-6-yloxy)pentyloxy]-5-methoxy-2-nitrobenzoyl pyrrolidine-2-carboxaldehyde diethyl thioacetal (2c).
The compound 2c was prepared following the method described for the compound 2a, employing 1c (549 mg, 1 mmol) and the crude product was purified by column chromatography to afford the compound 2c as a yellow oil.
(593 mg, 84% (2S)-N-4-[3-(2-Phenyl-4-oxo-4H-[1]benzopyran-6-yloxy)propoxy]-5-methoxy-2-aminobenzoyl pyrrolidine-2-carboxaldehyde diethyl thioacetal (3a) . The compound 3a (679 mg, 1 mmol) dissolved in methanol (20 mL) and added SnCl 2 .2H 2 O (1.13 gr, 5 mmol) was refluxed for 5 h. The reaction mixture was cooled and the methanol was evaporated under vacuum and the residue was carefully adjusted to pH 8 with saturated NaHCO 3 solution and then extracted with ethyl acetate (2x30 mL). The combined organic phase was washed with brine (15 mL), dried over anhydrous Na 2 SO 4 and evaporated under vacuum to afford the amino diethyl thioacetal 3a as yellow oil (506 mg, 78%) and this was directly used in the next step.
(2S)-N-4-[4-(2-Phenyl-4-oxo-4H-[1]benzopyran-6-yloxy)butoxy]-5-methoxy-2-aminobenzoyl pyrrolidine-2-carboxaldehyde diethyl thioacetal (3b).
The compound 3b was prepared following the method described for the compound 3a, employing the compound 2b (693 mg, 1 mmol) to afford the amino diethyl thioacetal 3b as a yellow oil (510 mg, 77%).
(2S)-N-4-[5-(2-Phenyl-4-oxo-4H-[1]benzopyran-6-yloxy)pentyloxy]-5-methoxy-2-aminobenzoyl pyrrolidine-2-carboxaldehyde diethyl thioacetal (3c).
The compound 3c was prepared following the method described for the compound 3a, employing the compound 2c (707 mg, 1 mmol) to afford the amino diethyl thioacetal 3c as a yellow oil (528 mg, 78%). -(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one (4a) . A solution of amino thioacetal 3a (649 mg, 1 mmol), HgCl 2 (597 mg, 2.2 mmol) and CaCO 3 (240 mg, 2.4 mmol) in acetonitrilewater (4:1) was stirred slowly at room temperature for 12 h, until TLC indicate the complete disappearance of starting material. The reaction mixture was diluted with ethyl acetate (30 mL) and filtered through a celite. The clear yellow organic supernatant was extracted with ethyl acetate (2x20 mL). The organic layer was washed with saturated NaHCO 3 (20 mL), brine (20 mL) and the combined organic phase was dried over anhydrous Na 2 SO 4 . The organic layer was evaporated under vacuum and the crude product was purified by column chromatography (5% CHCl 3 -MeOH) to afford the compound 4a as a pale yellow solid (273 mg, 52%). This material was repeatedly evaporated from CHCl 3 in vacuum to generate the imine form, m. -(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one (4c) . The compound 4c was prepared following the method described for the compound 4a employing 3c (677 mg, 1 mmol), to afford the compound 4c as a pale yellow solid (298 mg, 54%) In vitro evaluation of cytotoxic activity. In vitro cytotoxicity was evaluated using human cancer cell lines HT-29, HCT-15, A-549,HOP-62 and SiHa. Viable cells were seeded in growth medium into 96-well microtiter plates and allowed to attach overnight. A protocol of 48 h continuous drug exposure was used, 18a and a sulforhodamine B (SRB) protein assay was used to estimate cell viability or growth. 
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